Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

and establishment of an international commercial hub in Switzerland, gain on disposal of investment in Vertex ($23.5 million), and tax effect of adjustments; and

d)Depreciation: Depreciation of $30.9 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.


 

Unaudited results for the three months to September 30, 2010

Non GAAP reconciliation

US GAAP Adjustments Non GAAP Acquis Divestments, Amorti itions & reorgan September -zation integr -izations & Reclas September 3 months to, 30, & asset -ation discontinued -sify 30, 2010 impairments activ operations deprec 2010 -ities -iation (a) (b) (c) (d) $M $M $M $M $M $M Total revenues 874.3 - - - - 874.3 Costs and expenses: Cost of product sales 112.7 - - (7.3) (2.3) 103.1 Research and development 197.9 - (45.0) - (4.4) 148.5 Selling, general and administrative 392.4 (73.9) - - (16.1) 302.4 Reorganization costs 9.7 - - (9.7) - - Integration and acquisition costs 5.8 - (5.8) - - - Depreciation - - - - 22.8 22.8 Total operating expenses 718.5 (73.9) (50.8) (17.0) - 576.8 Operating income 155.8 73.9 50.8 17.0 - 297.5 Interest income 1.0 - - - - 1.0 Interest expense (8.3) - - - - (8.3) Other income, net 0.8 - - - - 0.8 Total other expense, net (6.5) - - - - (6.5) Income before income taxes and equity in losses of equity method investees 149.3 73.9 50.8 17.0 - 291.0 Income taxes (52.7) (10.1) (3.5) (4.1) - (70.4) Equity in losses of equity method investees, net of tax (0.3) - - - - (0.3) Net income 96.3 63.8 47.3 12.9 - 220.3 Impact of convertible debt, net of tax (1) - 8.4 - - - 8.4 Numerator for diluted EPS 96.3 72.2 47.3 12.9 - 228.7 Weighted average number of shares (millions) - diluted 556.7 33.2 - - - 589.9 Diluted earnings per ADS 51.9c 33.8c 24.0c 6.6c - 116.3c

(1)    The impact of convertible debt, net of tax has a dilutive effec
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... that develops and commercializes proprietary technologies and products for ... results for the second fiscal quarter ended March 31, ... continued to advance business with our existing customers and ... President and CEO of SQI. "The delivery of a ...
(Date:5/21/2015)... May 21, 2015 Specialty Pharmacy ... and been admitted to BPA Worldwide as a ... will track audience data for Specialty Pharmacy Times ... , “By becoming a member of BPA Worldwide, ... providing our clients with the most reliable, unequaled ...
(Date:5/21/2015)... YORK , May 21, 2015  Prima Biomed ... company that is striving to become a leader in ... cancer, recently announced that the final CVac data from ... shown a clear trend for a clinically meaningful improvement ... in second remission patients. In the group ...
(Date:5/21/2015)... 21, 2015  The EveryLife Foundation for Rare ... and Amy Klobuchar (D-MN) today for ... & Treatments, or OPEN ACT. Supported ... organizations, this bipartisan legislation promises to rapidly bring ... rare disease patients by incentivizing drug makers to ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Specialty Pharmacy Times Joins BPA Worldwide 2Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
(Date:4/21/2015)... BURNABY, Canada , April 21, 2015 ... spending and evolving government policies are boosting access control ...   According to a recently published report ... & Opportunities, 2020 ", the access control systems market ... to nearly USD1.2 billion by 2020.The access control systems ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... how their brains operate, a study at the University of ... Emotion and the Brain," at the annual meeting of the ... to use fMRI scans to study the connections between perceived ... fMRI scans with data relevant to social behavior is part ...
... and conducted by the University of Miami,s Rosenstiel School ... School of Medicine, found that swimmers using public ocean ... and may increase their risk for potential staph infections ... found that if you swim in subtropical marine waters, ...
... silica particles used in biomedicine and engineering likely won,t ... to work presented today. The result should allay fears ... to the finest silica nanomaterials in industrial or commercial ... that, mostly, size doesn,t matter, by using total surface ...
Cached Biology News:Researchers shed new light on connection between brain and loneliness 2Researchers shed new light on connection between brain and loneliness 3Nanoparticle toxicity doesn't get wacky at the smallest sizes 2Nanoparticle toxicity doesn't get wacky at the smallest sizes 3
Mouse monoclonal [SPM302] to BCAR1, prediluted ( Abpromise for all tested applications). entrezGeneID: 9564 SwissProtID: P56945...
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Rabbit polyclonal to Myosin VIIa (rating: *****) ( Abpromise for all tested applications). entrezGeneID: 4647 SwissProtID: Q13402...
Mouse monoclonal [6E10] to LAP2 ( Abpromise for all tested applications). entrezGeneID: 7112 SwissProtID: P42166...
Biology Products: